Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2018-10-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document details a specific corporate action: the conversion of convertible loans into shares, resulting in an increase in the total number of shares and the share capital as of October 31, 2018. This directly relates to changes in the company's capital structure. The text explicitly mentions the increase in shares and share capital due to debt conversion. This aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is a notification, the core content is the capital change itself, not just an announcement of a report (RPA) or a general regulatory filing (RNS). The document concludes with an 'Attachment' link, but the primary purpose is to disclose the capital change details.
2018-10-31 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding where the holder, Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension, crossed a threshold, resulting in a new holding percentage of 10.02%. The document explicitly states the 'Reason for major shareholding notification Buy' and provides detailed tables of shares and voting rights before and after the transaction. This structure perfectly matches the definition of a Major Shareholding Notification.
2018-10-04 English
Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Regulatory Filings Classification · 95% confidence The document is a press release dated October 3, 2018, announcing the finalization and summarization of data from a Phase II study for a veterinary drug, Doxophos Vet. It details efficacy results (ORR, PFS) and safety profiles, and mentions the intent to seek conditional approval from the US FDA. This content—announcing key results and progress toward regulatory submission—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a formal presentation (IP), and it focuses on operational/clinical results rather than just management commentary (MDA), it fits best as an Earnings Release (ER) which often includes key operational/clinical milestones alongside financial updates, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the detailed results presentation, ER is a strong candidate, but since it is primarily a clinical/operational update rather than a standard quarterly financial summary, and it is a formal announcement of a major development, it aligns closely with the nature of an Earnings Release announcing key operational achievements that drive future revenue. However, looking closely at the definitions, it is a specific announcement of clinical trial results and future regulatory plans, which often falls under general regulatory announcements if not tied directly to a quarterly earnings period. Since it is a detailed announcement of a significant operational/clinical milestone, and not a short notice about a report being available, it is classified as an Earnings Release (ER) as it communicates key performance indicators (clinical success) that drive investor valuation, similar to how earnings highlights are presented. The document length (7297 chars) is substantial enough to be the primary communication, not just a notice (RPA).
2018-10-03 English
Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Earnings Release Classification · 99% confidence The document is titled "PRESS RELEASE" and announces positive efficacy and safety data from a Phase II study for a veterinary drug (Doxophos Vet). It summarizes key results, discusses adverse reactions, and mentions future plans for seeking conditional approval. This format—a formal announcement of recent operational or clinical results, often released to the public and investors before a full regulatory filing—is characteristic of an Earnings Release (ER) or a general press release announcing significant business updates. Since it focuses purely on clinical trial results and business progress rather than comprehensive financial statements (10-K, IR) or management changes (MANG), and it is not a transcript (CT) or a formal proxy/governance document, the best fit among the provided options is Earnings Release (ER), as these releases often contain operational highlights and clinical milestones alongside or instead of pure financial figures, especially for biotech/pharma companies. It is not a Report Publication Announcement (RPA) because it contains the substantive data summary itself, not just a notice that a report is available. Given the context of a clinical trial update, ER is the most appropriate classification for this type of material announcement. FY 2018
2018-10-03 English
Oasmia presenterar positiva effekt- och säkerhetsdata för Doxophos Vet i studie med tidigare obehandlade hundar med lymfom
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated 2018-10-03. It announces positive efficacy and safety data for a veterinary drug (Doxophos Vet) from a Phase II study and states that this data is sufficient for AdvaVet Inc. to apply for conditional approval in the US in H1 2019. It presents key results (Overall Response Rate, Progression-Free Survival) in a table format, typical of an initial results announcement, rather than a comprehensive regulatory filing like a 10-K or a full Interim Report (IR). The final paragraph explicitly states: "Denna information är sådan information som Oasmia Pharmaceutical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that Oasmia Pharmaceutical AB is obliged to disclose pursuant to the EU Market Abuse Regulation). This strongly indicates an immediate, periodic disclosure of material information, which aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses purely on clinical trial results and the plan to file for approval, and is not a transcript (CT) or a formal management discussion (MDA), it functions as an initial announcement of financial/operational results. Given the content is a press release announcing key results (efficacy data) that will impact future regulatory steps, it fits the definition of an Earnings Release (ER) which covers periodical financial/operational results highlights, even though the results here are clinical rather than purely financial. If it were just announcing that a full report was available, it would be RPA, but here the results themselves are the core announcement.
2018-10-03 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in the issuer (Vivesto AB). It explicitly mentions 'Resulting distribution of total holdings', 'Percentage of voting rights', and tracks the quantity of shares before and after a transaction, crossing a threshold (10%). This structure is characteristic of a Major Shareholding Notification, which reports changes in significant ownership levels.
2018-10-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.